Sixty years ago, Steele, Richardson and Olszewski designated progressive supranuclear palsy (PSP) as a new clinicopathological entity in their seminal paper. Since then, in addition to the classic Richardson’s syndrome (RS), different clinical phenotypic presentations have been linked with this four-repeat tauopathy. The clinical heterogeneity is associated with variability of regional distribution and severity of abnormal tau accumulation and neuronal loss. In PSP subtypes, the presence of certain clinical pointers may be useful for antemortem prediction of the underlying PSP-tau pathology. Midbrain atrophy on conventional MRI correlates with the clinical phenotype of RS but is not predictive of PSP pathology. Cerebrospinal fluid biomarkers and tau ligand positron emission tomography are promising biomarkers of PSP. A multidisciplinary approach to meet the patients’ complex needs is the current core treatment strategy for this devastating disorder.
Citations
Citations to this article as recorded by
PSP-Richardson syndrome mimics: An overview and pragmatic approach J. Necpál, M. Borsek, B. Jeleňová Revue Neurologique.2024; 180(1-2): 12. CrossRef
Mechanisms linking cerebrovascular dysfunction and tauopathy: Adding a layer of epiregulatory complexity Yoon A. Kim, Marian Mellen, Caghan Kizil, Ismael Santa‐Maria British Journal of Pharmacology.2024; 181(6): 879. CrossRef
Concomitant Medications for Progressive Supranuclear Palsy Jay M. Iyer, Douglas Gunzler, Anthony E. Lang, Lawrence I. Golbe, Alexander Pantelyat, Adam L. Boxer, Anne-Marie Wills JAMA Neurology.2024; 81(3): 295. CrossRef
SEND-PD in Parkinsonian Syndromes: Results of a Monocentric Cross-Sectional Study Linda Veith Sanches, Stephan Greten, Johanna Doll-Lee, Sophia Rogozinski, Johanne Heine, Lea Krey, Sarana Ulaganathan, Ida Jensen, Matthias Höllerhage, Sam Sani, Günter Höglinger, Florian Wegner, Martin Klietz Neuropsychiatric Disease and Treatment.2024; Volume 20: 1849. CrossRef
Existing statistical measures and techniques in detecting and evaluating progressive supranuclear palsy, its phenotypes by using MRI modalities: A Review Nirmal Adam Sait, J Kathirvelan Materials Today: Proceedings.2023; 80: 2000. CrossRef
The role of magnetic resonance imaging in the diff erential diagnosis of Parkinson’s disease A. A. Tappakhov, T. E. Popova Russian neurological journal.2023; 28(1): 5. CrossRef
Clinical features of progressive supranuclear palsy Yafei Wen, Qijie Yang, Bin Jiao, Weiwei Zhang, Jingyi Lin, Yuan Zhu, Qian Xu, Hui Zhou, Ling Weng, Xinxin Liao, Yafang Zhou, Junling Wang, Jifeng Guo, Xinxiang Yan, Hong Jiang, Beisha Tang, Lu Shen Frontiers in Aging Neuroscience.2023;[Epub] CrossRef
Midbrain area and the hummingbird sign from brain MRI in progressive supranuclear palsy and idiopathic normal pressure hydrocephalus Johan Virhammar, Harald Blohmé, Dag Nyholm, Charalampos Georgiopoulos, David Fällmar Journal of Neuroimaging.2022; 32(1): 90. CrossRef
Cognitive, Psychiatric, and Motor Symptoms–Based Algorithmic Approach to Differentiate Among Various Types of Dementia Syndromes Rehab Magdy, Mona Hussein Journal of Nervous & Mental Disease.2022; 210(2): 129. CrossRef
Idiopathic normal pressure hydrocephalus-like MRI features in patients with progressive supranuclear palsy: a comparative case-control study Halil Onder, Bilge Kocer, Selcuk Comoglu Neurological Research.2022; 44(9): 807. CrossRef
Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders M. Lopez-Cuina, W.G. Meissner Revue Neurologique.2022; 178(5): 460. CrossRef
Clinical Aspects of the Differential Diagnosis of Parkinson’s Disease and Parkinsonism Hae-Won Shin, Sang-Wook Hong, Young Chul Youn Journal of Clinical Neurology.2022; 18(3): 259. CrossRef
Dopamine transporter imaging in progressive supranuclear palsy: Severe but nonspecific to subtypes Qi‐Si Chen, Xin‐Yi Li, Ling Li, Jia‐Ying Lu, Yi‐Min Sun, Feng‐Tao Liu, Chuan‐Tao Zuo, Jian Wang Acta Neurologica Scandinavica.2022; 146(3): 237. CrossRef
CSF tau microtubule-binding region identifies pathological changes in primary tauopathies Kanta Horie, Nicolas R. Barthélemy, Salvatore Spina, Lawren VandeVrede, Yingxin He, Ross W. Paterson, Brenton A. Wright, Gregory S. Day, Albert A. Davis, Celeste M. Karch, William W. Seeley, Richard J. Perrin, Rama K. Koppisetti, Faris Shaikh, Argentina L Nature Medicine.2022; 28(12): 2547. CrossRef
Role of Multivoxel MR Spectroscopy Progressive Supranuclear Palsy – A Preliminary Study Sandhya Mangalore, Manoj Kumar, Pramod Pal, Jitender Saini, Shaik Pasha, Ravi Yadav Neurology India.2022; 70(6): 2388. CrossRef
Genetics of Progressive Supranuclear Palsy: A Review Yafei Wen, Yafang Zhou, Bin Jiao, Lu Shen Journal of Parkinson's Disease.2021; 11(1): 93. CrossRef
Disease course and treatment patterns in progressive supranuclear palsy: A real-world study John C. Morgan, Xiaolan Ye, Jennifer A. Mellor, Keisha J. Golden, Jorge Zamudio, Louis A. Chiodo, Yanjun Bao, Tao Xie Journal of the Neurological Sciences.2021; 421: 117293. CrossRef
Central nystagmus in progressive supranuclear palsy: A neglected clinical feature? Maja Klarendic, Manja Hribar, Nina Bozanic Urbancic, Nina Zupancic, Milica G. Kramberger, Maja Trost, Saba Battelino, Diego Kaski, Maja Kojovic Parkinsonism & Related Disorders.2021; 84: 15. CrossRef
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial Günter U Höglinger, Irene Litvan, Nuno Mendonca, Deli Wang, Hui Zheng, Beatrice Rendenbach-Mueller, Hoi-Kei Lon, Ziyi Jin, Nahome Fisseha, Kumar Budur, Michael Gold, Davis Ryman, Hana Florian, Anwar Ahmed, Ikuko Aiba, Alberto Albanese, Kelly Bertram, Yvet The Lancet Neurology.2021; 20(3): 182. CrossRef
A Study on the Essential and Parkinson’s Arm Tremor Classification Vasileios Skaramagkas, George Andrikopoulos, Zinovia Kefalopoulou, Panagiotis Polychronopoulos Signals.2021; 2(2): 201. CrossRef
Progressive Supranuclear Palsy: Improvement in Cognitive-Behavioral Disturbances and Motor-Function Disabilities Following Treatment With Antidepressants and Cholinesterase Inhibitors Michelle Oyeka, Terngu Ibilah, Jacob Israel, Jose Gavito-Higuera, Ricardo Salazar Cureus.2021;[Epub] CrossRef
Progressive supranuclear palsy N.V. Fedorova, E.V. Bril, T.K. Kulua, A.D. Mikhaylova Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2021; 121(5): 111. CrossRef
Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care Brent Bluett, Alexander Y. Pantelyat, Irene Litvan, Farwa Ali, Diana Apetauerova, Danny Bega, Lisa Bloom, James Bower, Adam L. Boxer, Marian L. Dale, Rohit Dhall, Antoine Duquette, Hubert H. Fernandez, Jori E. Fleisher, Murray Grossman, Michael Howell, Di Frontiers in Neurology.2021;[Epub] CrossRef
The Genetic Landscape of Parkinsonism-Related Dystonias and Atypical Parkinsonism-Related Syndromes Monica Diez-Fairen, Pilar Alvarez Jerez, Joos Berghausen, Sara Bandres-Ciga International Journal of Molecular Sciences.2021; 22(15): 8100. CrossRef
MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology Chihiro Sato, Nipun Mallipeddi, Nupur Ghoshal, Brenton A. Wright, Gregory S. Day, Albert A. Davis, Albert H. Kim, Gregory J. Zipfel, Randall J. Bateman, Audrey Gabelle, Nicolas R. Barthélemy Annals of Clinical and Translational Neurology.2021; 8(9): 1817. CrossRef
“Parkinson’s disease” on the way to progressive supranuclear palsy: a review on PSP-parkinsonism Ján Necpál, Miroslav Borsek, Bibiána Jeleňová Neurological Sciences.2021; 42(12): 4927. CrossRef
Estimation and discussion of prognosis in neurologic practice. Communication issues with patient with neurological disease E. V. Bril, A. V. Khasina, F. A. Abbasov, O. S. Zimnyakova, N. V. Fedorova Medical alphabet.2021; (22): 55. CrossRef
The Progressive Supranuclear Palsy: Past and Present Aspects Theodore P. Parthimos, Kleopatra H. Schulpis Clinical Gerontologist.2020; 43(2): 155. CrossRef
Machine Learning Techniques to Identify Dementia Nivedita Manohar Mathkunti, Shanta Rangaswamy SN Computer Science.2020;[Epub] CrossRef
My dad and progressive supranuclear palsy (PSP) Heather Angus-Leppan Practical Neurology.2020; 20(3): 263. CrossRef
Tauopathy and Movement Disorders—Unveiling the Chameleons and Mimics Jacky Ganguly, Mandar Jog Frontiers in Neurology.2020;[Epub] CrossRef
A Home-Based, Music-Cued Movement Program Is Feasible and May Improve Gait in Progressive Supranuclear Palsy Joanne E. Wittwer, Margaret Winbolt, Meg E. Morris Frontiers in Neurology.2019;[Epub] CrossRef
Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy Marcos C B Oliveira, Helen Ling, Andrew J Lees, Janice L Holton, Eduardo De Pablo-Fernandez, Thomas T Warner Journal of Neurology, Neurosurgery & Psychiatry.2019; 90(5): 555. CrossRef
Revisiting the diagnostic value of Evans’ index: lessons from an unusual case of normal pressure hydrocephalus with Evans’ index less than 0.3 Jung E. Park, Hyunjin Ju, Kayeong Im, Kyum-Yil Kwon Neurological Sciences.2019; 40(12): 2637. CrossRef
Progressive supranuclear palsy as differential diagnosis of Parkinson's disease in the elderly Ricardo Fernández-Ferreira, Raúl Anwar García-Santos, Mayela Rodríguez-Violante, Coral López-Martínez, Ivonne Karina Becerra-Laparra, María Eugenia Torres-Pérez Revista Española de Geriatría y Gerontología.2019; 54(5): 251. CrossRef
Neuroinflammation as a Common Feature of Neurodegenerative Disorders Leonardo Guzman-Martinez, Ricardo B. Maccioni, Víctor Andrade, Leonardo Patricio Navarrete, María Gabriela Pastor, Nicolas Ramos-Escobar Frontiers in Pharmacology.2019;[Epub] CrossRef
On the journey to uncover the causes of selective cellular and regional vulnerability in neurodegeneration Zane Jaunmuktane, Sebastian Brandner Acta Neuropathologica.2019; 138(5): 677. CrossRef
Clinical Milestones Preceding the Diagnosis of Multiple System Atrophy and Progressive Supranuclear Palsy: A Retrospective Cohort Study Louise Wiblin, Rory Durcan, Brook Galna, Mark Lee, David Burn Journal of Movement Disorders.2019; 12(3): 177. CrossRef
Prediction of the Clinical Severity of Progressive Supranuclear Palsy by Diffusion Tensor Imaging Yao-Liang Chen, Xiang-An Zhao, Shu-Hang Ng, Chin-Song Lu, Yu-Chun Lin, Jur-Shan Cheng, Chih-Chien Tsai, Jiun-Jie Wang Journal of Clinical Medicine.2019; 9(1): 40. CrossRef
Tauopathy with hippocampal 4‐repeat tau immunoreactive spherical inclusions: a report of three cases Gabor G. Kovacs, Linda K. Kwong, Murray Grossman, David J. Irwin, Edward B. Lee, John L. Robinson, Eunran Suh, Vivianna M. Van Deerlin, Virginia M. Lee, John Q. Trojanowski Brain Pathology.2018; 28(2): 274. CrossRef
A case of spinal anesthesia in a patient with progressive supranuclear palsy Momoka Tonan, Moritoki Egi, Nana Furushima, Satoshi Mizobuchi JA Clinical Reports.2018;[Epub] CrossRef
Is it Useful to Classify PSP and CBD as Different Disorders? Yes Helen Ling, Antonella Macerollo Movement Disorders Clinical Practice.2018; 5(2): 145. CrossRef
Difficulties in the diagnosis of four repeats (4R) tauopathic parkinsonian syndromes Piotr Alster, Ewa Krzyżanowska, Dariusz Koziorowski, Stanisław Szlufik, Dorota Różański, Joanna Noskowska, Justyna Mianowicz, Adrian Michno, Leszek Królicki, Andrzej Friedman Neurologia i Neurochirurgia Polska.2018; 52(4): 459. CrossRef
Neuro-ophthalmology of movement disorders Olga Waln, Joseph Jankovic Expert Review of Ophthalmology.2018; 13(5): 283. CrossRef
Role of Neuroimaging on Differentiation of Parkinson’s Disease and Its Related Diseases Toshihide Ogawa, Shinya Fujii, Keita Kuya, Shin-ichiro Kitao, Yuki Shinohara, Mana Ishibashi, Yoshio Tanabe Yonago Acta Medica.2018; 61(3): 145. CrossRef
Gait disorders in adults and the elderly Walter Pirker, Regina Katzenschlager Wiener klinische Wochenschrift.2017; 129(3-4): 81. CrossRef
Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease Steve Vucic, Matthew C. Kiernan Neurotherapeutics.2017; 14(1): 91. CrossRef
Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches Adam L Boxer, Jin-Tai Yu, Lawrence I Golbe, Irene Litvan, Anthony E Lang, Günter U Höglinger The Lancet Neurology.2017; 16(7): 552. CrossRef
Immunization therapy targeting α-synuclein has emerged as a promising approach for Parkinson’s disease and perhaps for other synucleinopathies. Several antibodies have shown therapeutic effects in mouse models of synucleinopathies and have alleviated the pathological and behavioral phenotypes of these mice. The mechanisms through which the immunization therapy works were initially puzzling, especially given that α-synuclein is a typical cytosolic protein. Recent studies, however, suggested that extracellular α-synuclein is an important pathogenic entity, and hence, a target for immunotherapy. Here, we review the literature describing immunization therapy for synucleinopathies in mouse models and provide current thoughts on the potential mechanisms underlying the therapeutic effects of α-synuclein immunotherapy.
Citations
Citations to this article as recorded by
Aggregation-Induced Emission Luminogens: A New Possibility for Efficient Visualization of RNA in Plants Zheng-Chao Yang, Li-Xiang Zhao, Yu-Qi Sang, Xin Huang, Xuan-Chen Lin, Zhi-Ming Yu Plants.2024; 13(5): 743. CrossRef
Oxidative Stress and Dopaminergic Metabolism: A Major PD Pathogenic
Mechanism and Basis of Potential Antioxidant Therapies Aamir Rasool, Robina Manzoor, Kaleem Ullah, Ramsha Afzal, Asad Ul-Haq, Hadia Imran, Imdad Kaleem, Tanveer Akhtar, Anum Farrukh, Sahir Hameed, Shahid Bashir CNS & Neurological Disorders - Drug Targets.2024; 23(7): 852. CrossRef
Effectiveness of Flavonoid-Rich Diet in Alleviating Symptoms of Neurodegenerative Diseases Aneta Szulc, Karolina Wiśniewska, Magdalena Żabińska, Lidia Gaffke, Maria Szota, Zuzanna Olendzka, Grzegorz Węgrzyn, Karolina Pierzynowska Foods.2024; 13(12): 1931. CrossRef
Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut Jacqui T. Nimmo, Harry Smith, Chang Yi Wang, Jessica L. Teeling, James A. R. Nicoll, Ajay Verma, Jean-Cosme Dodart, Zhi Liu, Feng Lin, Roxana O. Carare Acta Neuropathologica.2022; 143(1): 55. CrossRef
Autophagy-Related Pathways in Vesicular Unconventional Protein Secretion Shin Hye Noh, Ye Jin Kim, Min Goo Lee Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson’s Disease Irene Sanchez-Mirasierra, Saurav Ghimire, Sergio Hernandez-Diaz, Sandra-Fausia Soukup Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant Rachel Rose, Emma Mitchell, Piet Van Der Graaf, Daisuke Takaichi, Jun Hosogi, Hugo Geerts Journal of Pharmacokinetics and Pharmacodynamics.2022; 49(6): 593. CrossRef
Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases Falguni Baidya, Mariya Bohra, Aishika Datta, Deepaneeta Sarmah, Birva Shah, Priya Jagtap, Swapnil Raut, Ankan Sarkar, Upasna Singh, Kiran Kalia, Anupom Borah, Xin Wang, Kunjan R. Dave, Dileep R. Yavagal, Pallab Bhattacharya Immunology.2021; 162(2): 160. CrossRef
Electrogastrography for diagnosis of early-stage Parkinson's disease Nobuyuki Araki, Yoshitaka Yamanaka, Anupama Poudel, Yoshikatsu Fujinuma, Akira Katagiri, Satoshi Kuwabara, Masato Asahina Parkinsonism & Related Disorders.2021; 86: 61. CrossRef
Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity Simona S. Ghanem, Hend S. Fayed, Qi Zhu, Jia-Hong Lu, Nishant N. Vaikath, Janarthanan Ponraj, Said Mansour, Omar M. A. El-Agnaf Molecules.2021; 26(12): 3736. CrossRef
Tat-p27 Ameliorates Neuronal Damage Reducing α-Synuclein and Inflammatory Responses in Motor Neurons After Spinal Cord Ischemia Woosuk Kim, Hyun Jung Kwon, Hyo Young Jung, Kyu Ri Hahn, Seung Myung Moon, Yeo Sung Yoon, In Koo Hwang, Soo Young Choi, Dae Won Kim Neurochemical Research.2021; 46(12): 3123. CrossRef
Immunotherapies for Parkinson’s Disease: Progression of Clinical Development Jet Shee Teng, Yin Yin Ooi, Soi Moi Chye, Anna Pick Kiong Ling, Rhun Yian Koh CNS & Neurological Disorders - Drug Targets.2021; 20(9): 802. CrossRef
Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection Sheila K. Pirooznia, Liana S. Rosenthal, Valina L. Dawson, Ted M. Dawson, Eric Barker Pharmacological Reviews.2021; 73(4): 1204. CrossRef
Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here? Khalil Mallah, Christine Couch, Davis M. Borucki, Amer Toutonji, Mohammed Alshareef, Stephen Tomlinson Frontiers in Immunology.2020;[Epub] CrossRef
Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance Miguel Lemos, Serena Venezia, Violetta Refolo, Antonio Heras-Garvin, Sabine Schmidhuber, Armin Giese, Andrei Leonov, Sergey Ryazanov, Christian Griesinger, Gergana Galabova, Guenther Staffler, Gregor Karl Wenning, Nadia Stefanova Translational Neurodegeneration.2020;[Epub] CrossRef
Insights Into Peptide Inhibition of Alpha-Synuclein Aggregation James H. Torpey, Richard M. Meade, Ravina Mistry, Jody M. Mason, Jillian Madine Frontiers in Neuroscience.2020;[Epub] CrossRef
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy Jacqui T. Nimmo, Ajay Verma, Jean-Cosme Dodart, Chang Yi Wang, Jimmy Savistchenko, Ronald Melki, Roxana O. Carare, James A. R. Nicoll Alzheimer's Research & Therapy.2020;[Epub] CrossRef
Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives Khosro Jamebozorgi, Eskandar Taghizadeh, Daryoush Rostami, Hosein Pormasoumi, George E. Barreto, Seyed Mohammad Gheibi Hayat, Amirhossein Sahebkar Molecular Neurobiology.2019; 56(7): 4799. CrossRef
The Associations between Immunological Reactivity to the Haptenation of Unconjugated Bisphenol A to Albumin and Protein Disulfide Isomerase with Alpha-Synuclein Antibodies Datis Kharrazian, Martha Herbert, Aristo Vojdani Toxics.2019; 7(2): 26. CrossRef
Effects of single and combined immunotherapy approach targeting amyloid β protein and α‐synuclein in a dementia with Lewy bodies–like model Markus Mandler, Edward Rockenstein, Cassia Overk, Michael Mante, Jazmin Florio, Anthony Adame, Changyoun Kim, Radmila Santic, Achim Schneeberger, Frank Mattner, Sabine Schmidhuber, Gergana Galabova, Brian Spencer, Eliezer Masliah, Robert A. Rissman Alzheimer's & Dementia.2019; 15(9): 1133. CrossRef
Translational therapies for multiple system atrophy: Bottlenecks and future directions Nadia Stefanova Autonomic Neuroscience.2018; 211: 7. CrossRef
Integrin CD11b mediates α-synuclein-induced activation of NADPH oxidase through a Rho-dependent pathway Liyan Hou, Xiuqi Bao, Caixia Zang, Hanyu Yang, Fuqiang Sun, Yuning Che, Xuefei Wu, Shao Li, Dan Zhang, Qingshan Wang Redox Biology.2018; 14: 600. CrossRef
Serum titers of autoantibodies against α-synuclein and tau in child- and adulthood Isabell Kuhn, Tobias Rogosch, Theresa I. Schindler, Björn Tackenberg, Michael Zemlin, Rolf F. Maier, Richard Dodel, Yannick Kronimus Journal of Neuroimmunology.2018; 315: 33. CrossRef
Beneficial Effects of Flavonoids Against Parkinson's Disease Un Ju Jung, Sang Ryong Kim Journal of Medicinal Food.2018; 21(5): 421. CrossRef
Unconventional protein secretion – new insights into the pathogenesis and therapeutic targets of human diseases Jiyoon Kim, Heon Yung Gee, Min Goo Lee Journal of Cell Science.2018;[Epub] CrossRef
Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy Martin Kallab, Marcos Herrera-Vaquero, Malin Johannesson, Fredrik Eriksson, Jessica Sigvardson, Werner Poewe, Gregor K. Wenning, Eva Nordström, Nadia Stefanova Frontiers in Neuroscience.2018;[Epub] CrossRef
Gene therapy for neurological disorders: progress and prospects Benjamin E. Deverman, Bernard M. Ravina, Krystof S. Bankiewicz, Steven M. Paul, Dinah W. Y. Sah Nature Reviews Drug Discovery.2018; 17(9): 641. CrossRef
Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies Edward Rockenstein, Gary Ostroff, Fusun Dikengil, Florentina Rus, Michael Mante, Jazmin Florio, Anthony Adame, Ivy Trinh, Changyoun Kim, Cassia Overk, Eliezer Masliah, Robert A. Rissman The Journal of Neuroscience.2018; 38(4): 1000. CrossRef
Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects Julianna J. Tomlinson, Bojan Shutinoski, Li Dong, Fanyi Meng, Dina Elleithy, Nathalie A. Lengacher, Angela P. Nguyen, Greg O. Cron, Qiubo Jiang, Erik D. Roberson, Robert L. Nussbaum, Nour K. Majbour, Omar M. El-Agnaf, Steffany A. Bennett, Diane C. Lagace, Journal of Neural Transmission.2017; 124(6): 721. CrossRef
Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson’s Disease Xiaoli Si, Jiali Pu, Baorong Zhang Journal of Movement Disorders.2017; 10(2): 69. CrossRef
Membrane Trafficking Illuminates a Path to Parkinson’s Disease Takafumi Hasegawa, Naoto Sugeno, Akio Kikuchi, Toru Baba, Masashi Aoki The Tohoku Journal of Experimental Medicine.2017; 242(1): 63. CrossRef
Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model J. Teister, F. Anders, S. Beck, S. Funke, H. von Pein, V. Prokosch, N. Pfeiffer, F. Grus Scientific Reports.2017;[Epub] CrossRef
Impact of aging immune system on neurodegeneration and potential immunotherapies Zhanfeng Liang, Yang Zhao, Linhui Ruan, Linnan Zhu, Kunlin Jin, Qichuan Zhuge, Dong-Ming Su, Yong Zhao Progress in Neurobiology.2017; 157: 2. CrossRef
A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies Jess-Karan S. Dhillon, Cara Riffe, Brenda D. Moore, Yong Ran, Paramita Chakrabarty, Todd E. Golde, Benoit I. Giasson, Stephan N. Witt PLOS ONE.2017; 12(9): e0184731. CrossRef
Vaccination strategies in tauopathies and synucleinopathies Anne K. Braczynski, Jörg B. Schulz, Jan‐Philipp Bach Journal of Neurochemistry.2017; 143(5): 467. CrossRef
Missions of <italic>Journal of Movement Disorders</italic> Yun Joong Kim Journal of Movement Disorders.2016; 9(1): 1. CrossRef
How strong is the evidence that Parkinson's disease is a prion disorder? Patrik Brundin, Jiyan Ma, Jeffrey H. Kordower Current Opinion in Neurology.2016; 29(4): 459. CrossRef
Jae-Hyeok Lee, Jongkyu Park, Ho-Sung Ryu, Hyeyoung Park, Young Eun Kim, Jin Yong Hong, Sang Ook Nam, Young-Hee Sung, Seung-Hwan Lee, Jee-Young Lee, Myung Jun Lee, Tae-Hyoung Kim, Chul Hyoung Lyoo, Sun Ju Chung, Seong Beom Koh, Phil Hyu Lee, Jin Whan Cho, Mee Young Park, Yun Joong Kim, Young H. Sohn, Beom Seok Jeon, Myung Sik Lee
J Mov Disord. 2016;9(1):20-27. Published online January 25, 2016
Objective Neurodegeneration with brain iron accumulation (NBIA) represents a group of inherited movement disorders characterized by iron accumulation in the basal ganglia. Recent advances have included the identification of new causative genes and highlighted the wide phenotypic variation between and within the specific NBIA subtypes. This study aimed to investigate the current status of NBIA in Korea.
Methods We collected genetically confirmed NBIA patients from twelve nationwide referral hospitals and from a review of the literature. We conducted a study to describe the phenotypic and genotypic characteristics of Korean adults with atypical pantothenate kinase-associated neurodegeneration (PKAN).
Results Four subtypes of NBIA including PKAN (n = 30), PLA2G6-related neurodegeneration (n = 2), beta-propeller protein-associated neurodegeneration (n = 1), and aceruloplasminemia (n = 1) have been identified in the Korean population. The clinical features of fifteen adults with atypical PKAN included early focal limb dystonia, parkinsonism-predominant feature, oromandibular dystonia, and isolated freezing of gait (FOG). Patients with a higher age of onset tended to present with parkinsonism and FOG. The p.R440P and p.D378G mutations are two major mutations that represent approximately 50% of the mutated alleles. Although there were no specific genotype-phenotype correlations, most patients carrying the p.D378G mutation had a late-onset, atypical form of PKAN.
Conclusions We found considerable phenotypic heterogeneity in Korean adults with atypical PKAN. The age of onset may influence the presentation of extrapyramidal symptoms.
Citations
Citations to this article as recorded by
Typical pantothenate kinase-associated neurodegeneration caused by compound heterozygous mutations in PANK2 gene in a Chinese patient: a case report and literature review Yilun Tao, Chen Zhao, Dong Han, Yiju Wei, Lihong Wang, Wenxia Song, Xiaoze Li Frontiers in Neurology.2023;[Epub] CrossRef
The first Vietnamese patient who presented late onset of pantothenate kinase-associated neurodegeneration diagnosed by whole exome sequencing: A case report Van Khanh Tran, Chi Dung Vu, Hai Anh Tran, Nguyen Thi Kim Lien, Nguyen Van Tung, Nguyen Ngoc Lan, Huy Thinh Tran, Nguyen Huy Hoang Medicine.2023; 102(43): e34853. CrossRef
Genetic mutation spectrum of pantothenate kinase-associated neurodegeneration expanded by breakpoint sequencing in pantothenate kinase 2 gene Dahae Yang, Sanghyun Cho, Sung Im Cho, Manjin Kim, Moon-Woo Seong, Sung Sup Park Orphanet Journal of Rare Diseases.2022;[Epub] CrossRef
Long-Term Outcomes of Deep Brain Stimulation in Pantothenate Kinase-Associated Neurodegeneration-Related Dystonia Kyung Ah Woo, Han-Joon Kim, Seung-Ho Jeon, Hye Ran Park, Kye Won Park, Seung Hyun Lee, Sun Ju Chung, Jong-Hee Chae, Sun Ha Paek, Beomseok Jeon Journal of Movement Disorders.2022; 15(3): 241. CrossRef
Psychiatric symptoms in an adolescent reveal a novel compound heterozygous mutation of the PANK2 gene in the atypical PKAN syndrome Luz María González Huerta, Sorina Gómez González, Jaime Toral López Psychiatric Genetics.2021; 31(3): 95. CrossRef
Rational Design of Novel Therapies for Pantothenate Kinase–Associated Neurodegeneration Nivedita Thakur, Thomas Klopstock, Suzanne Jackowski, Enej Kuscer, Fernando Tricta, Aleksandar Videnovic, Hyder A. Jinnah Movement Disorders.2021; 36(9): 2005. CrossRef
Atypical Pantothenate Kinase-Associated Neurodegeneration with variable phenotypes in an Egyptian family Ali S. Shalash, Thomas W. Rösler, Ibrahim Y. Abdelrahman, Hatem S. Abulmakarem, Stefanie H. Müller, Franziska Hopfner, Gregor Kuhlenbäumer, Günter U. Höglinger, Mohamed Salama Heliyon.2021; : e07469. CrossRef
Treatment Responsiveness of Parkinsonism in Atypical Pantothenate Kinase‐Associated Neurodegeneration Jeanne Feuerstein, Caroline Olvera, Michelle Fullard Movement Disorders Clinical Practice.2020;[Epub] CrossRef
Diagnostic and clinical experience of patients with pantothenate kinase-associated neurodegeneration Randall D. Marshall, Abigail Collins, Maria L. Escolar, H. A. Jinnah, Thomas Klopstock, Michael C. Kruer, Aleksandar Videnovic, Amy Robichaux-Viehoever, Colleen Burns, Laura L. Swett, Dennis A. Revicki, Randall H. Bender, William R. Lenderking Orphanet Journal of Rare Diseases.2019;[Epub] CrossRef
Intrafamilial variability and clinical heterogeneity in a family with PLA2G6-associated neurodegeneration Jong Kyu Park, Jinyoung Youn, Jin Whan Cho Precision and Future Medicine.2019; 3(3): 135. CrossRef
On the complexity of clinical and molecular bases of neurodegeneration with brain iron accumulation C. Tello, A. Darling, V. Lupo, B. Pérez‐Dueñas, C. Espinós Clinical Genetics.2018; 93(4): 731. CrossRef
Looking Deep into the Eye-of-the-Tiger in Pantothenate Kinase–Associated Neurodegeneration J.-H. Lee, A. Gregory, P. Hogarth, C. Rogers, S.J. Hayflick American Journal of Neuroradiology.2018; 39(3): 583. CrossRef
Parkinson’s Disease and Metal Storage Disorders: A Systematic Review Edward Botsford, Jayan George, Ellen Buckley Brain Sciences.2018; 8(11): 194. CrossRef
Atypical pantothenate kinase-associated neurodegeneration: Clinical description of two brothers and a review of the literature S. Mahoui, A. Benhaddadi, W. Ameur El Khedoud, M. Abada Bendib, M. Chaouch Revue Neurologique.2017; 173(10): 658. CrossRef
Clinical rating scale for pantothenate kinase‐associated neurodegeneration: A pilot study Alejandra Darling, Cristina Tello, María Josep Martí, Cristina Garrido, Sergio Aguilera‐Albesa, Miguel Tomás Vila, Itziar Gastón, Marcos Madruga, Luis González Gutiérrez, Julio Ramos Lizana, Montserrat Pujol, Tania Gavilán Iglesias, Kylee Tustin, Jean Pie Movement Disorders.2017; 32(11): 1620. CrossRef
Missions of <italic>Journal of Movement Disorders</italic> Yun Joong Kim Journal of Movement Disorders.2016; 9(1): 1. CrossRef
Objective
Parkinsonism and other movement disorders have previously been reported in the acquired hepatocerebral degeneration associated with portosystemic shunting. However, there is no study to date about their prevalence as has been noted in
general practice.
Methods
One hundred and forty-three patients with hepatic cirrhosis from the gastroenterology clinic and internal medicine wards were enrolled. Liver data included the diagnoses, etiologies, assessments of complications, and treatments for cirrhosis. Hepatic encephalopathy was classified with regard to the West Haven criteria for semi-quantitative grading for mental status. Neurological
examination results and abnormal involuntary movements were recorded as primary outcomes. Neuro-radiology was used for the detection of severe brain lesions.
Results
Alcoholism was the most common cause of liver cirrhosis. Eighty-three patients (58%) presented with movement disorders. Asterixis was found in one of the cases. The most common movement disorder seen was an intentional tremor at 37.1%, which was followed by bradykinesia, Parkinsonism, and postural tremors at 29.4%, 10.5%, and 6.3%, respectively. The prevalence of movement disorders simultaneously increased with a high Child-Turcotte-Pugh score. The hepatic encephalopathy was grade 1 and 2. With the inclusion of age-range adjustments, we found that alcoholic cirrhosis and hepatic encephalopathy are statistically
significant factors [p < 0.05, odds ratio (OR) = 6.41, 95% confidence interval (CI) 1.38–29.71 and p < 0.001, OR = 13.65, 95% CI 4.71–39.54] for the development of movement disorders in non-Wilsonian cirrhotic patients. Conclusions
Intentional tremor is a common abnormal movement. Alcoholic cirrhosis and hepatic encephalopathy are significant risk factors in the development of movement disorders in non-Wilsonian cirrhotic patients.
Citations
Citations to this article as recorded by
Investigating the Relationship between Chronic Liver Cirrhosis and Parkinsonism: A Comparative Analysis and a Suggested Diagnostic Scheme Tal Sigawi, Omer Hamtzany, Noa Hurvitz, Yuval Ishay, Roy Dayan, David Arkadir, Yaron Ilan Clinics and Practice.2024; 14(4): 1375. CrossRef
A Prospective Study of the Prevalence of Parkinsonism in Patients With Liver Cirrhosis Diana Apetauerova, Peter Hildebrand, Stephanie Scala, Janet W. Zani, LeeAnne Lipert, Erin Clark, Tanya Fennell, Fredric D. Gordon Hepatology Communications.2021; 5(2): 323. CrossRef
Objective aaThe aim of this study was to investigate frontal N30 status in Parkinson’s disease (PD) and to examine the correlation between the amplitude of frontal N30 and the severity of motor deficits.
Methods aaThe frontal N30 was compared between 17 PD patients and 18 healthy volunteers. Correlations between the amplitude of frontal N30 and the Unified Parkinson’s Disease Rating Scale (UPDRS) motor score of the more severely affected side was examined.
Results aaThe mean latency of the N30 was not significantly different between patients and healthy volunteers (p = 0.981), but the mean amplitude was lower in PD patients (p < 0.025). There was a significant negative correlation between the amplitude of N30 and the UPDRS motor score (r = -0.715, p = 0.013).
Conclusions The frontal N30 status indicates the motor severity of PD. It can be a useful biomarker reflecting dopaminergic deficits and an objective measurement for monitoring the clinical severity of PD.
Citations
Citations to this article as recorded by
A Comparison of Sensorimotor Integration and Motor Fitness Components between Collegiate Athletes with and without Long COVID: A Cross-Sectional Study with Pair-Matched Controls Ibrahim M. Moustafa, Amal Ahbouch, Raheesa P. Kader, Tamer Mohamed Shousha, Abdulla Alrahoomi Journal of Clinical Medicine.2024; 13(9): 2469. CrossRef
Clinical factors affecting evoked magnetic fields in patients with Parkinson's disease Ryoji Naganuma, Ichiro Yabe, Megumi Takeuchi, Kirari Morishita, Shingo Nakane, Ryoken Takase, Ikuko Takahashi-Iwata, Masaaki Matsushima, Mika Otsuki, Hideaki Shiraishi, Hidenao Sasaki, Wing-ho Yung PLOS ONE.2020; 15(9): e0232808. CrossRef
Short-Term Effects of Thoracic Spine Manipulation on the Biomechanical Organisation of Gait Initiation: A Randomized Pilot Study Sébastien Ditcharles, Eric Yiou, Arnaud Delafontaine, Alain Hamaoui Frontiers in Human Neuroscience.2017;[Epub] CrossRef
Objective Galvanic vestibular stimulation (GVS) activates the vestibular afferents, and these changes in vestibular input exert a strong influence on the subject’s posture or standing balance. In patients with Parkinson’s disease (PD), vestibular dysfunction might contribute to postural instability and gait disorders.
Methods Current intensity was increased to 0.7 mA, and the current was applied to the patients for 20 minutes. To perform a sham stimulation, the current intensity was increased as described and then decreased to 0 mA over the course of 10 seconds. The patient’s status was recorded continuously for 20 minutes with the patient in the supine position.
Results Three out of 5 patients diagnosed with PD with postural instability and/or abnormal axial posture showed a reduction in postural instability after GVS. The score for item 12 of the revised Unified Parkinson’s Disease Rating Scale part 3 was decreased in these patients.
Conclusions The mechanism of postural instability is complex and not completely understood. In 2 out of the 5 patients, postural instability was not changed in response to GVS. Nonetheless, the GVS-induced change in postural instability for 3 patients in our study suggests that GVS might be a therapeutic option for postural instability.
Citations
Citations to this article as recorded by
Vestibular dysfunction in Parkinson’s disease: a neglected topic Meilin Gui, Lingling Lv, Lixia Qin, Chunyu Wang Frontiers in Neurology.2024;[Epub] CrossRef
Vestibular Neurostimulation for Parkinson’s Disease: A Novel Device-Aided Non-Invasive Therapeutic Option K. Ray Chaudhuri, Karolina Poplawska-Domaszewicz, Naomi Limbachiya, Mubasher Qamar, Lucia Batzu, Aleksandra Podlewska, Kristen Ade Journal of Personalized Medicine.2024; 14(9): 933. CrossRef
Beyond balance: The role of the Vestibular system in action recognition Roberto Gammeri, Maria-Chiara Villa, Tommaso Ciorli, Anna Berti, Raffaella Ricci Heliyon.2024; 10(18): e38019. CrossRef
Impact of galvanic vestibular stimulation electrode current density on brain current flow patterns: Does electrode size matter? Dennis Q. Truong, Alexander Guillen, Mujda Nooristani, Maxime Maheu, Francois Champoux, Abhishek Datta, Mohammad Ali Salehinejad PLOS ONE.2023; 18(2): e0273883. CrossRef
The Effectiveness of Electrical Vestibular Stimulation (VeNS) on Symptoms of Anxiety: Study Protocol of a Randomized, Double-Blinded, Sham-Controlled Trial Teris Cheung, Joyce Yuen Ting Lam, Kwan Hin Fong, Yuen Shan Ho, Alex Ho, Calvin Pak-Wing Cheng, Julie Sittlington, Yu-Tao Xiang, Tim Man Ho Li International Journal of Environmental Research and Public Health.2023; 20(5): 4218. CrossRef
Acceptability and feasibility of a vestibular nerve stimulation headset protocol in children with cerebral palsy Karen McConnell, Daniel Topley, Jason McKeown, Claire Kerr BMC Pediatrics.2022;[Epub] CrossRef
Effect of galvanic vestibular stimulation on axial symptoms in Parkinson’s disease Hiroshi Kataoka, Yohei Okada, Takao Kiriyama, Yorihiro Kita, Junji Nakamura, Koji Shomoto, Kazuma Sugie Journal of Central Nervous System Disease.2022; 14: 117957352210815. CrossRef
Galvanic vestibular stimulation and its applications: a systematic review Anna Paula Batista de Ávila Pires, Tatiana Rocha Silva, Maíra Soares Torres, Maria Luiza Diniz, Maurício Campelo Tavares, Denise Utsch Gonçalves Brazilian Journal of Otorhinolaryngology.2022; 88: S202. CrossRef
Detection and assessment of Parkinson's disease based on gait analysis: A survey Yao Guo, Jianxin Yang, Yuxuan Liu, Xun Chen, Guang-Zhong Yang Frontiers in Aging Neuroscience.2022;[Epub] CrossRef
EFFECT OF VESTIBULAR STIMULATION ON BEHAVIORAL CHANGES IN PARKINSON DISEASE-INDUCED MICE Ram Mohan, Mohan Jayabal, Rashmi Ramanathan, Jeevithan Shanmugam, Archana R Asian Journal of Pharmaceutical and Clinical Research.2022; : 84. CrossRef
IMPACT OF CALORIC VESTIBULAR STIMULATION ON CO-ORDINATION IN PARKINSON DISEASE INDUCED MICE RAM MOHAN, KAYALVIZHI, RASHMI RAMANATHAN, JEEVITHAN SHANMUGAM, ARCHANA R. International Journal of Pharmacy and Pharmaceutical Sciences.2022; : 46. CrossRef
The effect of galvanic vestibular stimulation on postural balance in Parkinson's disease: A systematic review and meta-analysis Mohammad Mahmud, Zaeem Hadi, Mabel Prendergast, Matteo Ciocca, Abdel Rahman Saad, Yuscah Pondeca, Yen Tai, Gregory Scott, Barry M. Seemungal Journal of the Neurological Sciences.2022; 442: 120414. CrossRef
A systematic review of vestibular stimulation in cerebral palsy Daniel Topley, Karen McConnell, Claire Kerr Disability and Rehabilitation.2021; 43(23): 3291. CrossRef
The link between lateral trunk flexion in Parkinson’s disease and vestibular dysfunction: a clinical study Haiyan Tang, You Chen, Zhidong Cen, Zhiyuan Ouyang, Danning Lou, Ying Tan, Wei Luo International Journal of Neuroscience.2021; 131(6): 521. CrossRef
Vestibular stimulation: a noninvasive brain stimulation in Parkinson’s disease & its implications Thanalakshmi Jagadeesan, Archana Rajagopal, Senthilkumar Sivanesan Journal of Complementary and Integrative Medicine.2021; 18(4): 657. CrossRef
Current perspectives on galvanic vestibular stimulation in the treatment of Parkinson’s disease Soojin Lee, Aiping Liu, Martin J. McKeown Expert Review of Neurotherapeutics.2021; 21(4): 405. CrossRef
Caloric and galvanic vestibular stimulation for the treatment of Parkinson’s disease: rationale and prospects David Wilkinson Expert Review of Medical Devices.2021; 18(7): 649. CrossRef
Early balance impairment in Parkinson’s Disease: Evidence from Robot-assisted axial rotations Alessandro Zampogna, Ilaria Mileti, Francesca Martelli, Marco Paoloni, Zaccaria Del Prete, Eduardo Palermo, Antonio Suppa Clinical Neurophysiology.2021; 132(10): 2422. CrossRef
Dizziness in Parkinson’s disease patients is associated with vestibular function Jeong-Ho Park, Suk Yun Kang Scientific Reports.2021;[Epub] CrossRef
c-Fos Expression after Stochastic Vestibular Stimulation and Levodopa in 6-OHDA Hemilesioned Rats Ghazaleh Samoudi, Andrea Nilsson, Thomas Carlsson, Filip Bergquist Neuroscience.2020; 424: 146. CrossRef
Sensory Neuromodulation Robert D. Black, Lesco L. Rogers Frontiers in Systems Neuroscience.2020;[Epub] CrossRef
Efficacy of transmastoidal galvanic stimulation on recovery outcomes in patients with unilateral peripheral vestibular disorders: a randomized controlled trial Reham Ali Mohamed Ali Ahmed, Ebtesam Mohamed Fahmy, Amina Mohamed Awad, Mona Mohamed Hamdy, Hussein Ahmed Abd Rahman Shaker The Egyptian Journal of Neurology, Psychiatry and Neurosurgery.2020;[Epub] CrossRef
Effect of caloric vestibular stimulation on brain neurochemicals in rotenone induced mouse model of Parkinson’s disease Sai Sailesh Kumar G, Srilatha Bashetti International Journal of Clinical Biochemistry and Research.2020; 7(1): 49. CrossRef
The Effect of L-dopa on Postural Stability in Parkinson’s Disease Patients Jacek Wilczyński, Natalia Habik Applied Sciences.2019; 9(3): 409. CrossRef
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease Fabio Bello, Mario Giannella, Gianfabio Giorgioni, Alessandro Piergentili, Wilma Quaglia Biomolecules.2019; 9(4): 142. CrossRef
Aplicações dos potenciais evocados miogênicos vestibulares: revisão sistemática de literatura Tatiana Rocha Silva, Marco Aurélio Rocha Santos, Luciana Macedo de Resende, Ludimila Labanca, Júlia Fonseca de Morais Caporali, Marjore Rhaissa de Sousa, Denise Utsch Gonçalves Audiology - Communication Research.2019;[Epub] CrossRef
Caloric vestibular stimulation for the management of motor and non-motor symptoms in Parkinson's disease David Wilkinson, Aleksandra Podlewska, Sarah E. Banducci, Tracy Pellat-Higgins, Martin Slade, Mayur Bodani, Mohamed Sakel, Lanty Smith, Peter LeWitt, Kristen K. Ade Parkinsonism & Related Disorders.2019; 65: 261. CrossRef
Deterioration of postural deformity in Parkinson’s disease patients with punding and hobbyism Ryoma Aoki, Makoto Shiraishi, Kyohei Mikami, Tsutomu Kamo Journal of Clinical Neuroscience.2019; 69: 179. CrossRef
Recent advancements in lateral trunk flexion in Parkinson disease Hiroshi Kataoka, Kazuma Sugie Neurology Clinical Practice.2019; 9(1): 74. CrossRef
Galvanic Vestibular Stimulation (GVS) Augments Deficient Pedunculopontine Nucleus (PPN) Connectivity in Mild Parkinson's Disease: fMRI Effects of Different Stimuli Jiayue Cai, Soojin Lee, Fang Ba, Saurabh Garg, Laura J. Kim, Aiping Liu, Diana Kim, Z. Jane Wang, Martin J. McKeown Frontiers in Neuroscience.2018;[Epub] CrossRef
Effects of Galvanic Vestibular Stimulation on Upper and Lower Extremities Motor Symptoms in Parkinson’s Disease Mahta Khoshnam, Daniela M. C. Häner, Eunice Kuatsjah, Xin Zhang, Carlo Menon Frontiers in Neuroscience.2018;[Epub] CrossRef
Vestibular Functions and Parkinson's Disease Paul F. Smith Frontiers in Neurology.2018;[Epub] CrossRef
Body Posture, Postural Stability, and Metabolic Age in Patients with Parkinson’s Disease Jacek Wilczyński, Agnieszka Pedrycz, Dariusz Mucha, Tadeusz Ambroży, Dawid Mucha BioMed Research International.2017; 2017: 1. CrossRef
Vestibular Deficits in Neurodegenerative Disorders: Balance, Dizziness, and Spatial Disorientation Thomas Cronin, Qadeer Arshad, Barry M. Seemungal Frontiers in Neurology.2017;[Epub] CrossRef
Vestibular neuromodulation: stimulating the neural crossroads of psychiatric illness Steven M Miller Bipolar Disorders.2016; 18(6): 539. CrossRef
Non-Invasive Neuromodulation Using Time-Varying Caloric Vestibular Stimulation Robert D. Black, Lesco L. Rogers, Kristen K. Ade, Heather A. Nicoletto, Heather D. Adkins, Daniel T. Laskowitz IEEE Journal of Translational Engineering in Health and Medicine.2016; 4: 1. CrossRef
Objective To evaluate changes in the strength and mechanical properties of neck muscles and disability in patients with cervical dystonia (CD) during a 12-week period following botulinum neurotoxin (BoNT) injections.
Methods Eight patients with CD volunteered for this prospective clinical cohort study. Patients had received BoNT injections regularly in neck muscles at three-month intervals for several years. Maximal isometric neck strength was measured by a dynamometer, and the mechanical properties of the splenius capitis were evaluated using two myotonometers. Clinical assessment was performed using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) before and at 2, 4, 8, and 12 weeks after the BoNT injections.
Results Mean maximal isometric neck strength at two weeks after the BoNT injections decreased by 28% in extension, 25% in rotation of the affected side and 17% in flexion. At four weeks, muscle stiffness of the affected side decreased by 17% and tension decreased by 6%. At eight weeks, the muscle elasticity on the affected side increased by 12%. At two weeks after the BoNT injections, the TWSTRS-severity and TWSTRS-total scores decreased by 4.3 and 6.4, respectively. The strength, muscle mechanical properties and TWSTRS scores returned to baseline values at 12 weeks.
Conclusions Although maximal neck strength and muscle tone decreased after BoNT injections, the disability improved. The changes observed after BoNT injections were temporary and returned to pre-injection levels within twelve weeks. Despite having a possible negative effect on function and decreasing neck strength, the BoNT injections improved the patients reported disability.
Citations
Citations to this article as recorded by
Paravertebral Muscle Mechanical Properties and Spinal Range of Motion in Patients with Acute Neck or Low Back Pain: A Case-Control Study Sandra Alcaraz-Clariana, Lourdes García-Luque, Juan Luis Garrido-Castro, César Fernández-de-las-Peñas, Cristina Carmona-Pérez, Daiana Priscila Rodrigues-de-Souza, Francisco Alburquerque-Sendín Diagnostics.2021; 11(2): 352. CrossRef
Paravertebral Muscle Mechanical Properties in Patients with Axial Spondyloarthritis or Low Back Pain: A Case-Control Study Sandra Alcaraz-Clariana, Lourdes García-Luque, Juan Luis Garrido-Castro, I. Concepción Aranda-Valera, Lourdes Ladehesa-Pineda, María Ángeles Puche-Larrubia, Cristina Carmona-Pérez, Daiana Priscila Rodrigues-de-Souza, Francisco Alburquerque-Sendín Diagnostics.2021; 11(10): 1898. CrossRef
Transient Hemichorea-hemiballism Induced by a Combination of Postprandial Hypotension and Severe Stenosis of the Innominate Artery Concomitant with Left Carotid Occlusion Sho Okune, Mikito Hayakawa, Tenyu Hino, Takato Hiramine, Taisuke Akimoto, Masayuki Sato, Yoshiro Ito, Aiki Marushima, Tomoya Takada, Eiichi Ishikawa, Akira Tamaoka, Yuji Matsumaru Internal Medicine.2024; 63(4): 577. CrossRef
Spicy foods triggering clinical symptoms in Moyamoya angiopathy Souvik DUBEY, Ritwik GHOSH, Subhankar CHATTERJEE, Mahua J. DUBEY, Biman K. RAY, Shambaditya DAS, Apratim CHATTERJEE, Durjoy LAHIRI, Markus KRAEMER Journal of Neurosurgical Sciences.2021;[Epub] CrossRef
Corticostriatal Hypermetabolism in Moyamoya Disease-Induced Hemichorea: Two Case Reports and a Literature Review Wen-biao Xian, Xiang-song Zhang, Xin-chong Shi, Gan-hua Luo, Chang Yi, Zhong Pei Frontiers in Neurology.2021;[Epub] CrossRef
Transient Ischemic Attack after Eating Spicy Foods in Children: Think of Moya Moya Disease Thomas Mathew, DelonD Souza, SajiK John, GG Sharath Kumar Neurology India.2021; 69(4): 1032. CrossRef
Asymmetric lenticulostriate arteries in patients with moyamoya disease presenting with movement disorder: three new cases Jiali Xu, Sijie Li, Gary B. Rajah, Wenbo Zhao, Changhong Ren, Yuchuan Ding, Qian Zhang, Xunming Ji Neurological Research.2020; 42(8): 665. CrossRef
Movement Disorders Following Cerebrovascular Lesions: Etiology, Treatment Options and Prognosis Do-Young Kwon Journal of Movement Disorders.2016; 9(2): 63. CrossRef